BiotechTube
SynerFuse

SynerFuse

Minneapolis, United States· Est.
synerfuse.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

SynerFuse is a private, pre-revenue medical device innovator targeting the significant unmet need for chronic pain management in spinal fusion patients. The company has developed the NeuroFuse System, an implantable pulse generator and lead system designed to be implanted concurrently with fusion hardware to provide direct nerve stimulation. Having completed a 15-patient proof-of-concept feasibility study under an FDA IDE, the company is positioned to advance its integrated therapy. It aims to improve surgical outcomes, reduce post-operative opioid reliance, and lower the overall economic burden of chronic back pain.

Chronic PainNeuroscience

Technology Platform

The NeuroFuse System, an implantable pulse generator and lead system that delivers Ultra Low Energy (ULE) direct nerve stimulation. It is designed to be implanted concurrently with spinal fusion hardware at the same surgical level to address neuropathic pain.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The massive and growing market of chronic low back pain, with over 1 million annual back surgeries in the U.S., presents a significant addressable opportunity.
An integrated solution that improves fusion surgery outcomes and reduces long-term opioid use could command a premium and see rapid adoption if clinical data is strong.
The hardware-agnostic design lowers barriers to surgeon adoption.

Risk Factors

Major clinical and regulatory risk: the device must prove safe and effective in larger pivotal trials for FDA approval.
Market adoption risk includes convincing surgeons to change practice and securing favorable insurance reimbursement.
Competition from large, established neuromodulation and spine companies is a constant threat.

Competitive Landscape

SynerFuse's primary competition includes large medical device companies like Medtronic, Boston Scientific, and Abbott, which dominate the traditional spinal cord stimulation market for failed back surgery syndrome. Its unique integrated approach differentiates it, but these giants have the resources to develop similar products. It also competes indirectly with all alternative pain management therapies, including pharmaceuticals, physical therapy, and other interventional procedures.

More companies in Digital Health & Biotech SaaS →More companies in United States →